A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

Clinical trial NCT07206498 · RECRUITING

Trial details

NCT number: NCT07206498
Sponsor: Wayshine Biopharm, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer (NSCLC)

Start date: 2025-10-17
Primary completion: 2028-10-14
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.